Comparing Mainz Biomed (NASDAQ:MYNZ) & Freedom Acquisition I (NASDAQ:FACT)

Freedom Acquisition I (NASDAQ:FACT) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares Freedom Acquisition I and Mainz Biomed”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Freedom Acquisition I	N/A	N/A	$5.98 million	N/A	N/A
Mainz Biomed	$659,935.00	17.85	-$21.65 million	($65.60)	-0.02

Freedom Acquisition I has higher earnings, but lower revenue than Mainz Biomed.

Risk and Volatility

Freedom Acquisition I has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Profitability

This table compares Freedom Acquisition I and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Freedom Acquisition I	N/A	-31.14%	1.67%
Mainz Biomed	N/A	N/A	N/A

Insider and Institutional Ownership

55.8% of Freedom Acquisition I shares are owned by institutional investors. 0.2% of Freedom Acquisition I shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Freedom Acquisition I and Mainz Biomed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Freedom Acquisition I	1	0	0	0	1.00
Mainz Biomed	1	1	0	0	1.50

Summary

Mainz Biomed beats Freedom Acquisition I on 5 of the 8 factors compared between the two stocks.

About Freedom Acquisition I

Freedom Acquisition I Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. Freedom Acquisition I Corp. was incorporated in 2020 and is based in New York, New York.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.